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1 Neuroimmunology Group, Functional and System Neurobiology Department, Instituto Cajal, Madrid, Spain, 2 VivaCell Biotechnology España, Parque Cientı́fico
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Abstract
Phytocannabinoids that do not produce psychotropic effects are considered of special interest as novel therapeutic agents
in CNS diseases. A cannabigerol quinone, the compound VCE-003, has been shown to alleviate symptoms in a viral model of
multiple sclerosis (MS). Hence, we studied T cells and macrophages as targets for VCE-003 and its efficacy in an autoimmune
model of MS. Proliferation, cell cycle, expression of activation markers was assessed by FACs in human primary T cells, and
cytokine and chemokine production was evaluated. Transcription was studied in Jurkat cells and RAW264.7 cells were used
to study the effects of VCE-003 on IL-17-induced macrophage polarization to a M1 phenotype. Experimental autoimmune
encephalomyelitis (EAE) was induced by myelin oligodendrocyte glycoprotein (MOG35–55) immunization and spinal cord
pathology was assessed by immunohistochemistry. Neurological impairment was evaluated using disease scores. We show
here that VCE-003 inhibits CD3/CD28-induced proliferation, cell cycle progression and the expression of the IL-2Ra and
ICAM-1 activation markers in human primary T cells. VCE-003 inhibits the secretion of Th1/Th17 cytokines and chemokines
in primary murine T cells, and it reduces the transcriptional activity of the IL-2, IL-17 and TNFa promoters induced by CD3/
CD28. In addition, VCE-003 and JWH-133, a selective CB2 agonist, dampened the IL-17-induced polarization of macrophages
to a pro-inflammatory M1 profile. VCE-003 also prevented LPS-induced iNOS expression in microglia. VCE-003 ameliorates
the neurological defects and the severity of MOG-induced EAE in mice through CB2 and PPARc receptor activation. A
reduction in cell infiltrates, mainly CD4+ T cells, was observed, and Th1 and Th17 responses were inhibited in the spinal cord
of VCE-003-treated mice, accompanied by weaker microglial activation, structural preservation of myelin sheets and
reduced axonal damage. This study highlights the therapeutic potential of VCE-003 as an agent for the treatment of human
immune diseases with both inflammatory and autoimmune components.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating
disease of the CNS and the main cause of non-traumatic
neurological disability in young adults. Supported by experimental
evidence largely collected from an important animal model,
experimental autoimmune encephalomyelitis (EAE), MS is con-
sidered a predominantly T cell-mediated autoimmune disease.
Although the exact cause of MS remains unclear, CNS
inflammation is a key element in the pathophysiology of this
disease. The histopathological hallmarks of MS include neuroin-
flammation, reflected by the migration of leukocyte infiltrates into
the central nervous system (CNS), and the loss of myelin and
axonal damage [1]. Indeed, Focal plaques of demyelination are
observed in the white matter of the brain and spinal cord [2]. EAE
is a CD4+ T cell–mediated autoimmune disease characterized by
perivascular CD4+ T cell and mononuclear cell inflammation,
with subsequent primary demyelination of axonal tracks in the
CNS that provokes progressive hind-limb paralysis [3]. In the EAE
model, nervous tissue inflammation is characterized by the
activation of microglia [4,5], which may amplify damage by
releasing mediators of toxicity and cytokines. Based on the
essential role of the autoimmune response in MS and in EAE [6],
immunomodulatory agents have been tested and approved for MS
therapy. However, these treatments are associated with side effects
and their effectiveness is limited.
Phytocannabinoids (pCBs) that do not produce psychotropic
effects, such as cannabidiol (CBD), cannabigerol (CBG), D9
tetrahydrocannabivarin (D9THCV) and cannabidivarin (CBDV)
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[7], are considered of special interest as novel therapeutic agents in
CNS diseases. In the CNS, there is evidence that CB1 receptors
play a fundamental role in neuroprotection [8], while CB2
receptors expressed primarily in microglia regulate microglial
neurotoxicity [9]. Besides the classical membrane CB receptors,
nuclear PPARc receptors have also been shown to be activated by
pCBs, and since they attenuate neuroinflammation, pCBs may be
of therapeutic interest for the treatment of inflammatory diseases
[10].
Preclinical and clinical data have shown that both Th1 and
Th17 cells are associated with autoimmune diseases, including MS
[11]. Moreover, there is evidence that Th17 cells play a crucial
role in EAE, perhaps more intensely in the initial phases of disease,
and Th1 cells probably contribute to disease pathogenesis by
exerting a more pronounced effect later in its development. EAE is
strongly suppressed in mice lacking IL-17 or the IL-17R, and
specific inhibition of IL-17 attenuates CNS inflammation [12–14].
However, the mechanism by which IL-17 participates in the
pathogenesis of EAE is still unclear. It was recently shown that IL-
17 mediates inhibition of oligodendrocyte maturation and deletion
of the NF-kB activator 1 in NG2+ glial cells, a key transducer of
IL-17 signaling, reduces EAE severity [15]. IL-17 also modulates
the differentiation of macrophages to the pro-inflammatory M1
phenotype [16]. Moreover, it has been suggested that IL-17 could
disrupt tight junctions in the blood-brain barrier (BBB) through
the induction of reactive oxygen species (ROS), allowing
peripheral autoimmune cells to penetrate the CNS [17,18].
Therefore, inhibition of IL-17 production by Th17 cells, and IL-
17 signaling on target cells, has opened new avenues to find an
effective therapy for MS.
Although there are few studies about the pharmacological
actions of CBG, one of the most significant in the context of
inflammation is its benefits in experimental inflammatory bowel
[19] by reducing nitric oxide production by macrophages through
activation of CB2 receptors. We have developed a series of new
cannabinoid quinones, including the CBG quinone named VCE-
003 that is a PPARc and CB2 receptor agonist [20]. We have
shown that VCE-003 alleviates neuroinflammation and motor
deficits in the viral TMEV-IDD model of MS [20], however, its
mode of action and cellular targets are still to be defined. In the
present study, we investigated whether T lymphocytes might be
direct targets of VCE-003 by using in vitro approaches. In human
primary T cells, VCE-003 inhibited CD3/CD28-induced prolif-
eration, cell cycle progression and the expression of the activation
markers IL-2Ra and ICAM-1. VCE-003 also inhibited the
secretion of Th1/Th17 cytokines and chemokines in primary T
cells, and it reduced the transcriptional activity of the IL-2, IL-17
and TNFa promoters induced by CD3/CD28 in Jurkat cells. In
addition, VCE-003 blunted IL-17-induced polarization of macro-
phages to a pro-inflammatory M1 profile. Therefore, we assessed
whether VCE-003 may be effective in an autoimmune model of
MS, such as EAE. We immunized C57BL/6 mice with MOG35–55
peptide to induce EAE, and tested the effect of treatment with
VCE-003 on the development and progression of EAE. Our
findings indicate that VCE-003 attenuated EAE by activating CB2
and PPARc receptors. Specifically, we observed a reduction of cell
infiltrates, mainly that of CD4+ cells, and inhibition of Th1 and
Th17 responses in the spinal cord of VCE-003-treated mice,
accompanied by decreased microglial activation, structural pres-
ervation of myelin sheets and reduced axonal damage.
Methods
Cell lines and reagents
Jurkat, BV2 and RAW264.7 cells were maintained at 37uC in a
humidified atmosphere containing 5% CO2 in RPMI supple-
mented with 10% fetal calf serum (FCS), 2 mM L-glutamine and
1% (v/v) penicillin/streptomycin (complete medium). VCE-003
was synthesized as previously described [20], while AM630,
T0070907 and WIN-55,212-2 were obtained from Cayman Chem
(Ann Arbor, MI, USA), and JWH-133 was purchased from Tocris
Bioscience (Bristol, UK). All other reagents were from Sigma Co
(St Louis, MO, USA).
Induction and assessment of EAE
All experiments were performed in strict accordance with EU
and governmental regulations (Decret 53/2013 BOE nu34 and
Comunidad de Madrid: ES 280790000184). The Ethics Commit-
tee on Animal Experimentation of the Instituto Cajal, CSIC
approved all procedures described in this study (protocol number:
2013/03 CEEA-IC). Measures to improve welfare assistance and
clinical status as well as endpoint criteria were established to
minimise suffering and ensure animal welfare. Briefly, wet food
pellets are placed on the bed-cage when the animals begin to
develop clinical signs to facilitate access to food and hydration.
Mice suffering severe disease (score 5) were euthanized in
accordance with our ethical guidelines. Female C57BL/6 mice
were purchased from Harlan (Barcelona, Spain) and housed in our
animal facilities (Instituto Cajal, CSIC, Madrid, Spain) under the
following controlled conditions: 12 h light/dark cycle; temperature
20uC (62uC) and 40–50% relative humidity with free access to
standard food and water. EAE was induced in female mice at 6–8
weeks of age by subcutaneous immunization with MOG35–55
(300 mg: peptide synthesis section, CBM, CSIC, Madrid, Spain)
and 200 mg of Mycobacterium tuberculosis (H37Ra Difco, Franklin
Lakes, NJ, USA) in a 1:1 mix with incomplete Freund’s adjuvant
(CFA, Sigma-Aldrich, Madrid, Spain). On the same day and 2
days later, mice were injected intraperitoneally (ip) with 200 ng of
pertussis toxin (Sigma-Aldrich, Madrid, Spain) in 0.1 ml PBS.
Control animals (CFA) were inoculated with the same emulsion
without MOG and they did not receive pertussis toxin. Treatment
started at day 6 post-immunization (p.i.) and consisted in daily
injections of VCE-003 (5 mg/kg) or of the vehicle alone (DMSO/
PBS) for the following 21 days. In some experiments, mice
received a combination of VCE-003 and the CB2 antagonist
AM630 (2 mg/kg), administered 15 min before VCE-003, or the
combination of VCE-003 and the PPARc antagonist T0070907
(5 mg/kg) injected 15 minutes before VCE-003. The mice were
examined daily for clinical signs of EAE and disease scores were
measured as follows: 0, no disease; 1, limp tail; 2, limp tail and
hind limb weakness; 3, hind limb paralysis; 4, hind limb and front
limb paralysis; 5, moribund and death. Groups: Intact, CFA, EAE
+ VEH; EAE + VCE-003; EAE + VCE-003 + AM630*; EAE +
VCE-003 + T0070907. All animals were sacrificed 28 days (p.i.)
for further analysis. * 4 animals from the EAE + VCE-003 +
AM630 group were sacrificed due to disease severity (score 5).
Tissue processing and Immunohistochemistry (IHC)
Mice were anesthetized by ip administration of pentobarbital
(50 mg/kg body weight) and they were transcardially perfused
with saline. Spinal cords were fixed in 4% paraformaldehyde in
0.1 M PBS, washed in 0.1 M PBS, cryoprotected with a 15% and
then a 30% solution of sucrose in 0.1 M PBS, and frozen at
280uC. Free-floating thoracic spinal cord sections (15/30 mm
thick) were washed three times for 10 min with 0.1 M phosphate
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buffer (PB). Endogenous peroxidase activity was inhibited with
50% methanol and 1.66% hydrogen peroxide. The sections were
blocked with 0.1% Triton X-100 and 5% animal serum and then
incubated overnight at 4uC in blocking buffer with the primary
antibody. For IHC in 30 mm sections, microglia cells were stained
with a rabbit anti-mouse Iba-1 antibody (1:1,000; Wako Chemical
Pure Industry, Osaka, Japan) and a primary rat anti-mouse CD4
antibody (1:1,000; BD Pharmingen; San Diego, CA, USA) was
used to detect CD4+ T cells (sections of 30 mm thick). In 15 mm
thick sections, a mouse anti-mouse SMI32 antibody (1:1,000;
Covance; San Diego, CA, USA) was used to detect axonal
damage, while for immunofluorescence, myelin was stained with a
RIP antibody (1:1,000; DSHB; University of Iowa, IA, USA) and
axons with a Neurofilament H antibody (1:1,000; Millipore;
Billerica, MA, USA). After incubation with the primary antibody
the sections were rinsed with PB three times for 10 min and then
incubated for 1 h with the secondary antibody: biotinylated goat
anti-rabbit (Iba-1); fluorescent goat anti-rabbit (Neurofilament H);
biotinylated rabbit anti-rat (CD4); fluorescent goat anti-mouse
(RIP); and biotinylated horse anti-mouse (SMI32). For immuno-
fluorescence visualization, sections were rinsed with PB three times
for 10 min and mounted. For immunostaining with DAB, after
rinsing the sections were incubated for 1 h with a biotin-
peroxidase complex (Vector Laboratories Inc.; Burlingame, CA,
USA) and then with the chromogen 3,39diaminobenzidine
tetrahydrochloride (DAB; Sigma-Aldrich; St. Louis, MO, USA).
After staining, the sections were dehydrated, cleared with xylene
and coverslipped. In all cases specificity of staining was confirmed
by omitting the primary antibody. Staining was quantified using
the Image J software designed by the National Institutes of Health
(NIH; Bethesda, MD, USA).
Luxol Fast Blue (LFB) staining
Free-floating thoracic spinal cord sections (15 mm thick) were
washed three times for 10 min in 0.1 M PB. The samples were
dehydrated in increasing concentrations of ethanol, from 70% to
95% and they were then incubated in LFB solution overnight at
56uC. The following day, the excess stain was rinsed off with 95%
ethyl alcohol, and the slides differentiated in the lithium carbonate
solution for 30 seconds. Sections were dehydrated, cleared with
xylene and cover slipped.
Inflammatory infiltrates
Thoracic slices were stained with Nissl solution at 50uC for
10 min and the sections were then dehydrated in 100% ethyl
alcohol, cleared in xylene and cover slipped. Inflammatory
infiltrates were evaluated on a scale of 0 to 4, the score reflecting
the amount of infiltrates in the thoracic spinal cord sections. A
score of 4 reflects the largest number of infiltrates with all the
intermediate scores (1, 2 and 3) to define the increase in the density
of infiltrates in the spinal cord tissue.
Microscopy and image analysis
Six thoracic spinal cord sections per animal from at least 6
animals per group were taken. Staining was quantified using the
Image J software (NIH; Bethesda, MD, USA). Sections were
analyzed by immunofluorescence on a Leica TCS SP5 confocal
microscope and with a Zeiss Axiocam high-resolution digital color
camera for IHC.
Real-time RT-PCR
Total RNA was isolated from the spinal cord of control (CFA),
EAE + VEH and EAE + VCE-003 treated animals. Spinal cord
sections from at least 6 animals were analyzed per group. Total
RNA (1 mg) was retrotranscribed using the iScriptTM cDNA
Synthesis Kit (Bio-Rad; Hercules, CA, USA), and the cDNA
generated was analyzed by real-time PCR, using the iQTM SYBR
Green Supermix (Bio-Rad; Hercules, CA, USA). Real-time PCR
was performed using a CFX96 Real-Time PCR Detection System
(Bio-Rad; Hercules, CA, USA). The GAPDH gene was used to
standardize mRNA expression in each sample and gene expression
was quantified using the 2-DDCt method. The oligonucleotide
primer sequences used are given in Table 1.
Western blotting
After treatments, BV2 cell cultures were lysed in Tris-buffered
saline (TBS, pH 7.6) containing 10% glycerol, 1% Nonidet P-40,
EDTA 1 mM, EGTA 1 mM plus a complete protease inhibitors
cocktail (Roche Diagnostics; Mannheim, Germany). The cell
lysates were mixed with 5x Laemmli sample buffer and boiled for
5 min. Equal amounts of protein (30 mg) were resolved on 10%
SDS-PAGE and electroblotted for 70 min at 90 V and 4uC to
nitrocellulose (Amersham Biosciences; Amersham, UK). The
membranes were blocked for 1 h at RT in 5% (w/v) dry skim
milk (Sveltesse, Nestlé; Barcelona, Spain) diluted in TBS with
0.1% TweenH 20 (TBST) and the membranes were then probed
overnight at 4uC with the antibody against iNOS diluted in 5%
milk-TBST (1:1,000; BD Pharmingen; San Diego, CA, USA).
After extensive washing with 5% milk-TBST and antibody
binding was detected for 1 h at room temperature with a
horseradish peroxidase-conjugated anti-goat secondary antibody
(1:4,000; Bio-Rad; Hercules, CA, USA), which was visualized after
rinsing enhanced chemiluminescence (Amersham Biosciences;
Amersham, UK). The blots were stripped in 62.5 mM Tris-HCl,
pH 6.8, containing 2% SDS and 0.7% b-mercaptoethanol and the
were reprobed with a monoclonal antibody against a-Tubulin
(1:10,000; Sigma; Madrid, Spain).
Isolation of human peripheral T cells and proliferation
assays
All experiments conducted on human material were approved
by the Ethics committee for Biomedical Research of the University
of Córdoba. Peripheral blood mononuclear cells (PBMC) were
isolated by Ficoll–Hypaque density gradient centrifugation from
buffy coats of blood donors obtained from the blood bank of the
Hospital Universitario Reina Sofı́a Córdoba, Spain. Human
peripheral T cells were isolated using a Pan T cell isolation kit
(Miltenyi Biotech; Madrid, Spain) and 105 cells were cultured in
triplicate in 96-well round bottom microtiter plates in 200 ml of
complete medium. The cells were then stimulated with the anti-
CD3 antibody OKT3 (coated 1 mg/ml) and the anti-CD28
antibody 15E8 (0.5 mg/ml) in the presence or absence of
increasing concentrations of VCE-003. The cultures were
maintained for three days and pulsed with 0.5 mCi [3H]TdR/
well for the last 12 h of culture, measuring the radioactivity
incorporated into DNA by liquid scintillation counting.
Cytofluorimetric analyses of cell surface antigen, cell
cycle and cellular division
To analyze the cell cycle and measure CD25 expression,
peripheral T cells (106/ml) were stimulated with for 72 h anti-
CD3 and anti-CD28 antibodies in 24 well plates in a total volume
of 2 ml complete medium in the presence or absence of different
concentrations of VCE-003. The expression of CD25 and CD54
at the cell surface was measured by fluorescence using a specific
mAb (CD54: PE anti-human CD54; BD Pharmingen; San Diego,
Cannabigerol Quinone and EAE Pathogenesis
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CA, USA; CD25: Mouse Anti-Human interleukin-2 receptor;
Dako; Glostrup, Denmark), which was analyzed by flow cytometry
in a FACSCAnto II flow cytometer. To analyze the DNA profile,
the cells were washed in PBS and fixed in ethanol (70%, for 24 h
at 4uC), before digesting their RNA (RNAseA, 50 U/ml) and
staining them with propidium iodide (20 mg/ml) to be analyzed by
cytofluorimetry. Ten thousand gated events were collected per
sample and the percentage of cells in each phase of the cell cycle
was determined. To analyze cell division, purified T cells were
stained with carboxy-fluorescein succinimidyl ester (CSFE) and
stimulated with anti-CD3 (coated 1 mg/ml) and anti-CD28 (coated
0.5 mg/ml) antibodies in the presence or absence of VCE-003 for 6
days and the percentage of proliferating cells (defined as weak
CFSE fluorescence) was determined by flow cytometry.
Cytokine detection
Peripheral T cells (106/ml) were stimulated with anti-CD3
(coated 1 mg/ml) and anti-CD28 (0.5 mg/ml) antibodies in 24 well
plates for 72 h in the presence or absence of different concentra-
tions of VCE-003. The supernatants were collected and the
cytokines and chemokines were detected using the semiquantita-
tive Human Cytokine Array Kit, Panel A (R&D System;
Minneapolis, MN, USA) according to the manufacturer’s recom-
mendations. Pixel densities on developed X-Ray films were
collected with a scanner and analyzed using the ImageJ processing
and analysis program (NIH; Bethesda, MD, USA).
Transient transfection and Luciferase assays
Jurkat cells (107/ml) were transiently transfected with the IL-2-
Luc, TNF-Luc and IL-17-Luc plasmids using the LipofectineTM
reagent (Life Technologies; Madrid, Spain), according to the
manufacturer’s recommendations. Twenty-four hours after trans-
fection, the cells were pre-treated with VCE-003 for 30 min and
stimulated for 6 h with the OKT3 (coated 1 mg/ml) and the anti-
CD28 antibody 15E8 (0.5 mg/ml). The cells were then lysed in
25 mM Tris-phosphate buffer [pH 7.8] containing 8 mM MgCl2,
1 mM DTT, 1% Triton X-100, and 7% glycerol. The luciferase
activity was quantified on an Autolumat LB 953 (EG&G Berthold;
Oak Ridge, TN, USA), following the manufacturer’s instructions
(Luciferase assay kit, Promega; Madison, WI, USA), and the
protein concentration was measured by the Bradford method. The
pGL4.74 vector (Promega; Madison, WI, USA) that contains a
constitutively expressed firefly luciferase gene served as an internal
control to normalize transfection efficiency and firefly and renilla
luciferase activities were measured using the Dual-LuciferaseH
reporter assay system (Promega; Madison, WI, USA). The
background obtained with the lysis buffer was subtracted from
each experimental value and the specific transactivation was
expressed as the fold induction relative to the untreated cells. All
the experiments were repeated at least three times.
Pro-inflammatory cytokine production by IL-17-
stimulated macrophages
Serum-starved RAW264.7 macrophages were pre-incubated
with JWH-133 (Tocris Bioscience; Bristol, UK) or VCE-003 for
18 h, before they were exposed for an additional 24 hours to
recombinant mouse IL-17 (50 ng/mL; R&D Systems; Minneap-
olis, MN, USA). The cells were collected in PBS and total RNA
was extracted using the RNeasy Mini Kit (Qiagen; Hilden,
Germany).
CB2 functional assay
CHO-CB2 cells were transfected with the CRE-luc plasmid that
contains six consensus cAMP responsive elements (CRE) linked to
firefly luciferase. The cells were treated for 6 h with forskolin
(FSK, 1 mM) 24 hours after transfection, in the presence or
absence of either WIN-55,212-2 (1 or 10 mM) or VCE-003
(5 mM), and the luciferase activity measured in the cell lysates.
Statistical analysis
For the course of EAE, the results are the mean 6 SD from 6 to
11 mice per group. Statistical analysis was performed using the
non-parametric Kruskal-Wallis test to compare the clinical score
each day. For in vitro experiments, every assay was performed in
duplicate and at least three independent experiments were
performed. In each assay performed, the mean and SD or SEM
were calculated, and plotted to visualize differences between the
average values of the experimental populations. The sample
population means were compared against the control population
means using an unpaired two-tailed Student’s t test. The p value
obtained from the Student’s t test analysis marks the probability of
rejecting the null hypothesis, that is, that the events are
independent, whereby: *p#0.05, significant; **p#0.01, very
significant; and ***p#0.005 or p#0.001, highly significant.
Table 1. The mouse primer sequences used in quantitative Polymerase Chain Reactions.
Genes Forward Reverse
IL-6 59 -GAACAACGATGATGCACTTGC- 39 59 -TCCAGGTAGCTATGGTACTCC- 39
IL-1b 59 -CTCCACCTCAATGGACAGAA- 39 59 -GCCGTCTTTCATTACACAGG- 39
Ccl2 59 -GGGCCTGCTGTTCACAGTT- 39 59 -CCAGCCTACTCATTGGGAT- 39
Ccl4 59 -AACAACATGAAGCTCTGCGT- 39 59 -AGAAACAGCAGGAAGTGGGA- 39
IFNc 59-CTCAAGTGGCATAGATGTGGAAG-39 59-GCTGGACCTGTGGGTTGTTGA-39
IL-17 59-CCTCAGACTACCTCAACCGTTC-39 59-TTCATGTGGTGGTCCAGCTTTC-39
iNOS 59 -AACGGAGAACGTTGGATTTG-39 59-CAGCACAAGGGGTTTTCTTC-39
ICAM-1 59 -CAGATGCCGACCCAGGAGAG-39 59 -ACAGACTTCACCACCCCGATG-39
TNFa 59 -AGAGGCACTCCCCCAAAAGA-39 59 -CGATCACCCCGAAGTTCCCATT-39
GAPDH 59-TGGCAAAGTGGAGATTGTTGCC-39 59-AAGATGGTGATGGGCTTCCCG-39
18S 59- ATGCTCTTAGCTGAGTGTCCCG-39 59 -ATTCCTAGCTGCGGTATCCAGG-39
doi:10.1371/journal.pone.0094733.t001
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Results
Immunosuppressive activity of VCE-003
It is believed that myelin specific T cells of a Th1 and Th17
phenotype can mediate EAE [21]. Thus, to investigate the effect of
VCE-003 on T cell activation we isolated human peripheral T
cells that were stimulated by the mAb mitogens anti-CD3 and
anti-CD28. DNA synthesis in CD3/CD28-stimulated T cells,
measured by [3H]-TdR uptake, was markedly inhibited by VCE-
003 in a concentration dependent manner (Figure 1A). This effect
of VCE-003 on cell proliferation was confirmed by stimulating
primary T cells with the CD3/CD28 mAbs for 6 days, and
evaluating the proportion of CSFE-stained daughter cells by flow
cytometry. We found that VCE-003 clearly prevented CD3/
CD28-induction of T cell division even at the lowest concentration
tested (Figure 1B).
T-cell receptor (TCR) engagement can induce different
functional outcomes, such as activation, proliferation or apoptosis,
and a second signal provided by CD28 can rescue T cells from
TCR-induced apoptosis and promote proliferation [22]. Unsti-
mulated T cells remained largely in the G0/G1 phase of the cell
cycle (Figure 1C) whereas three days after activation with CD3/
CD28, T cells were full cycling and progressed through the S, G2
and M phases of the cell cycle (16% of cells), while exposure to
VCE-003 (5 mM) almost completely prevented the entry of the
cells into the S-phase of the cell cycle (Figure 1C). Interestingly,
VCE-003 also prevented CD3/CD28 from inducing apoptosis,
evident through the percentage of hypodiploid cells (sub G0, 27%).
These results indicate that at the doses used, VCE-003 did not
induce cytotoxicity or apoptosis in primary T cells in culture.
We next assessed the effects of VCE-003 on the expression of
activation markers and on the secretion of pro-inflammatory
markers by CD3/CD28-stimulated primary T cells. The super-
natants of these cells were analyzed using the R&D Systems
Human Cytokine Array that detects the relative levels of 36
different cytokines, chemokines and acute phase proteins in a
single sample (Figure S1 in File S1). We found that CD3/CD28
stimulation induced the release of: Th1 related cytokines GM-
Figure 1. Effects of VCE-003 on T-cell proliferation. (A) Human peripheral T cells were stimulated with the OKT3 (1 mg/ml) and anti-CD28
(0.5 mg/ml) mAbs for 72 h in the presence or absence of increasing concentrations of VCE-003. Thymidine [3H] incorporation was measured by liquid
scintillation and represented as the mean d.p.m 6 SEM. Three independent experiments were performed. **p#0.01 and ***p#0.005 in an unpaired
two-tailed Student’s t test. (B) T cells were stained with CFSE, pre-treated with VCE-003 and stimulated with the CD3/CD28 mAbs for 6 days. Cell
division was identified by flow cytometry. (C) T-cells were pre-treated with VCE-003 and stimulated with the CD3/CD28 mAbs for 72 h. The
percentage of subdiploid cells (sub-G0), and cells entering the S and G2/M phases of the cell cycle are indicated. The results are representative of three
independent experiments.
doi:10.1371/journal.pone.0094733.g001
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CSF, INFc and TNFa; Th2 related cytokines, IL-17; the
chemokines RANTES, MIP-1a, MIP-1b and IP-10; and the
adhesion molecule sICAM-1, and pretreatment with 5 mM VCE-
003 inhibited the release of all these soluble mediators (Figure 2A
and 2B). The effect of VCE-003 on the cell surface expression of
the activation markers CD25 (IL-2Ra) and CD54 (ICAM-1) was
also studied in CD3/CD28-stimulated primary T cells. VCE-003
strongly inhibited the proportion of cells expressing the CD25 and
CD54 markers at the cell surface (Figure 2C). To gain insight into
the molecular mechanisms of cytokine inhibition Jurkat cells were
transiently transfected with the IL-2-Luc, TNFa-Luc and IL-17-
Luc plasmids that contain specific gene promoters fused to the
luciferase gene. VCE-003 (5 mM) inhibited the transcriptional
activity of the promoters induced by CD3/CD28 mAb stimulation
by nearly 60% (p,0.01 vs. control activated cells: Figure 2D) and
therefore, it is likely that the inhibitory mechanism of VCE-003
occurs both at the transcriptional and post-transcriptional levels.
VCE-003 dampens the IL-17-induced inflammatory
response of macrophages
Macrophages are also important effector cells that mediate the
immune responses in EAE. They act as antigen presenting cells
(APC), thereby activating an antigen-specific T cell response in the
periphery and CNS. Activation of the CB2 receptor was recently
shown to blunt IL-17-induction of M1 macrophages [16] and
therefore, we assessed whether in addition to directly inhibiting IL-
17 production by primary T cells, VCE-003 might also counteract
the functional properties of IL-17 on its target cells. Treatment of
RAW264.7 macrophages with IL-17 promoted their polarization
towards a pro-inflammatory M1 phenotype, as shown by increased
expression of M1 markers like TNFa, IL-6, IL-1b or Ccl2, and
Ccl4. However, exposing RAW264.7 macrophages to either the
CB2 agonist JWH-133 or VCE-003 strongly inhibited the
induction of M1 markers by IL-17 (Figure 3A and 3B). Moreover,
we show that VCE-003 is a functional CB2 agonist (Figure 3C) by
using CHO-CB2 cells transfected with the CRE-luc plasmid and
treated with FSK. Taken together, these data strongly suggest that
Figure 2. Effects of VCE-003 on T-cell activation. (A) Human peripheral T cells were stimulated for 72 h with the OKT3 (1 mg/ml) and anti-CD28
(0.5 mg/ml) mAbs in the presence or absence of increasing concentrations of VCE-003, and the culture supernatants were collected and assayed using
a R&D Systems Human Cytokine Array system (A, cytokines; B, chemokines and sICAM-1). (C) Human peripheral T cells were stimulated as indicated in
2A for 72 h, and the expression of CD25 and CD54 was detected by flow cytometry. The numbers represent the percentage of CD25+ and CD54+ cells
and they are representative of three different experiments. (D) Jurkat T cells transfected with TNFa, IL-17 or IL-2 promoter luciferase reporter plasmids
were treated for 30 min with increasing concentrations of VCE-003, and then stimulated with OKT3 (1 mg/ml) and anti-CD28 (0.5 mg/ml) mAbs for 6 h
before measuring luciferase activity in the cell lysates. The results are the means 6 SEM of three measurements and they are expressed as the
percentage of inhibition, considering CD3/CD28 stimulation as 100% activation: **p#0.01 indicates significant changes between CD3+CD28 and
VCE-003 treatment.
doi:10.1371/journal.pone.0094733.g002
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CB2 receptor activation by VCE-003 blunts IL-17 polarization of
M1 macrophages.
VCE-003 attenuates the clinical severity and
neuropathology of EAE
VCE-003 has been reported to display anti-inflammatory
properties in the Theiler’s virus model of MS [20]. On the basis
of the in vitro results described above we investigated the
therapeutic potential of VCE-003 in the autoimmune model of
the disease (EAE), performing the treatments at an early stage of
the disease since mice received the first injection of VCE-003 at
day 6 p.i. Subcutaneous immunization with MOG35-55 induced
EAE in all mice that received the vehicle alone, with disease
kinetics in these mice consistent with previous studies given the
mean onset on day 9 p.i. [23]. All vehicle-treated mice developed
a severe disease that peaked by day 17 p.i., and four moribund
animals were sacrificed on day 18 p.i. By contrast, the clinical
manifestations of EAE were attenuated in mice receiving daily
injections of VCE-003 (5 mg/kg, i.p.) from day 6 p.i. (Figure 4A).
In these mice that received VCE-003, the mean onset was on day
15 p.i. and the disease peaked on day 23 p.i., not reaching a score
of 1 throughout the course of the experiment (day 6-day 28).
Because VCE-003 acts as an agonist for the PPARc receptor
and it binds to the CB2 receptor [20], we wanted to determine the
receptor type involved in the beneficial effects of VCE-003 in
EAE. Thus, we administered a selective antagonist for the CB2
receptor (AM630) or for the PPARc receptor (T0070907) in
combination with VCE-003, and we found that that the benefits of
VCE-003 were significantly counteracted by the administration of
the CB2 antagonist AM630, particularly in the induction phase. In
fact, the disease peaked on day 15 p.i. in both groups that received
the CB2 antagonist AM630: the EAE vehicle control mice and the
EAE-VCE-003 treated mice. Treatment with the PPARc receptor
antagonist, the compound T0070907, also attenuated the effects of
VCE-003 but to a lesser extent, and the peak disease onset was
only delayed to day 22 p.i. These data suggest the involvement of
both receptors in the capacity of VCE-003 to ameliorate EAE. We
also observed that EAE mice treated with VCE-003 showed
significantly less infiltrates than EAE control mice that the received
vehicle alone (Figure 4B). Interestingly, VCE-003 treatment
Figure 3. VCE-003 and JWH-133 reduces IL-17-induced M1 polarization in macrophages. Serum starved RAW264.7 cells were exposed to
either JWH-133 (5 mM) or VCE-003 (1 and 2.5 mM) for 18 h and then maintained for 24 h in the presence or absence of recombinant mouse IL-17
(50 ng/ml). A) RT-PCR analysis of M1 gene expression in JWH-133-treated RAW264.7 cells. B) RT-PCR analysis of M1 gene expression in VCE-003-
treated RAW264.7 cells. The results are expressed as the fold change with respect to untreated cells and they are the mean 6 SEM of four
independent experiments. C) CHO-CB2 cells were transiently transfected with the CRE-luc plasmid and then exposed to FSK (1 mM) for 6 h in the
presence or absence of the indicated concentrations of WIN-55,212-2 (1 or 10 mM) and VCE-003 (5 mM) before luciferase activity was measured in the
cell lysates. The results are expressed as the means 6 SEM of three determinations and they are expressed as the percentage inhibition considering
FSK stimulation as 100% activation: *p,0.05, **p,0.01 and ***p,0.005 in an unpaired two-tailed Student’s t test.
doi:10.1371/journal.pone.0094733.g003
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Figure 4. VCE-003 alleviates EAE and prevents CD4+ cells infiltration. (A) VCE-003 significantly ameliorates the clinical signs and disease
progression of EAE (squares), and these effects are partially blocked by a CB2 antagonist (AM630, triangles) or PPARc antagonist (T0070907, circles).
The results are shown as the means 6 SD: *p = 0.015 EAE + VCE-003 vs EAE + VEH; **p = 0.005 EAE + VCE-003 vs EAE + VEH; ***p,0.001 EAE + VCE-
003 vs EAE + VEH; #p = 0.016 EAE + VCE-003 + AM630 vs EAE + VCE-003; ##p = 0.008 EAE + VCE-003 + AM630 vs EAE + VCE-003; ###p,0.001 EAE
+ VCE-003 + AM630 vs EAE + VCE-003; +p = 0,009 EAE + VCE-003 + T0070907 vs EAE + VCE-003; ++p,0.01 EAE + VCE-003 + T0070907 vs EAE + VCE-
003. (B) VCE-003 reduces the number of infiltrates and (C) it significantly reduces the number of CD4+ T cells in thoracic spinal cord sections. The
figure shows the representative staining of spinal cord sections: LFB (B) and CD4 immunohistochemistry (C). Arrows indicate CD4+ T cells. The results
(C) are shown as the means 6 SEM: **p = 0,004 vs Intact; #p = 0,030 vs EAE + VEH.
doi:10.1371/journal.pone.0094733.g004
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reduced the number of CD4+ T cells in the spinal cord of EAE
mice (Figure 4C).
Histopathological analysis of spinal cord tissue showed that the
extensive microglia/macrophage activation in the spinal cord of
EAE mice evident by Iba-1 immunohistochemistry was dramat-
ically reduced by VCE-003 (Figure 5A) and when quantified
(Figure 5B), VCE-003 significantly decreased microglial activation
(p,0.05). Moreover, whereas important areas of demyelination
were stained by LFB in vehicle-treated mice, a pronounced
reduction in demyelination was evident in EAE mice that received
VCE-003 (Figure 5D). This was confirmed by myelin protein RIP
staining, which showed clear myelin disruption in the spinal cord
of control EAE mice (Figure 5C) while VCE-003 administration
contributed to the maintenance of myelin structure.
VCE-003 reduces axonal damage in EAE mice
To further evaluate the potential of VCE-003 as neuroprotec-
tive agent, we compared the axonal damage in EAE mice that
received the vehicle alone or VCE-003 by assessing neurofilament
and SMI32 labeling. In representative coronal thoracic spinal cord
sections, neurofilament staining highlights the disorganization of
the white matter tracts in EAE control mice, in contrast to the
thoracic spinal cord structure evident in intact animals or those
EAE mice that received VCE-003 (Figure 6A). Longitudinal spinal
cord sections stained with neurofilament (Figure 6B) show the
swelling and deformation of the axons, and the ovoid formation in
EAE control mice. Axon lesions were less frequent in the mice that
received VCE-003 and they had markedly less damage that was
particularly evident when the longitudinal spinal cord sections
labeled with SMI32 (Figure 6C).
Reduced inflammatory mediators in EAE mice that
received VCE-003
The expression of inflammatory mediators was studied by
isolating total mRNA from the spinal cords of mice at chronic
stages of the disease (28 days p.i.). Quantitative real time PCR was
performed using primers specific for the pro-inflammatory
cytokines TNFa, IFNc, IL-1b and IL-17, and the expression of
transcripts for the adhesion molecule ICAM-1 and the inducible
nitric oxide synthase (iNOS) was also quantified. A similar analysis
was performed with RNA isolated from the same region of the
spinal cord from CFA mice. Compared with the untreated mice,
there was a significant increase in all the inflammatory markers
studied in EAE mice that received the vehicle alone (Figure 7A
and 7B). By contrast, there was a significant decrease in TNFa,
IFNc, IL-17, ICAM-1 and iNOS expression in the EAE mice that
received VCE-003, while there was also a tendency towards
reduced IL-1b expression (p = 0.075). To investigate whether
VCE-003 targeted microglial cells in the induction of iNOS we
evaluate the expression of this protein in Western blots of cultured
BV2 microglial cells (Figure 7C) in which VCE-003 (1 mM)
significantly reduced the expression of iNOS induced by exposure
to LPS/IFNc. The effect of VCE-003 on iNOS expression was
blocked by the CB2 receptor antagonist AM630 (1 mM) and
likewise, the blockade of PPARc receptors by GW96662 (0.1 mM)
reversed the inhibitory effects of VCE-003 (1 mM) on LPS/IFNc-
induced iNOS expression. These results indicate that both CB2
and PPARc receptors were involved in the anti-inflammatory
effects of VCE-003 in BV2 cells.
Discussion
This study provides evidence that the cannabigerol quinone
derivative, VCE-003, suppresses in vitro T cell responses, that it
dampens the pro-inflammatory cytokine production by IL-17-
stimulated macrophages and attenuates the pathology develop-
ment of EAE induced by MOG immunization. This improvement
is evident through several measures of EAE pathology, including: a
decreased neurological deficit score; reduced inflammatory cell
infiltration, in particular that of CD4+ T cells; demyelination and
axonal damage in the spinal cord.
The mechanisms underlying the improvement in EAE induced
by VCE-003 treatment are not clear, although the suppression of
immune and inflammatory cell activity seems to be involved. In
accordance with its pharmacological profile, the activation of both
PPARc and CB2 receptors appear to be implicated in the
amelioration of EAE by VCE-003 [20]. Microglia/macrophages
play a dual role in the pathogenesis of MS as they contribute to
lesion formation and axonal damage, but they also support repair
mechanisms [24]. The activation of microglia has been closely
associated with the development of histopathological lesions, and
Figure 5. VCE-003 significantly reduces microglial activation and preserves myelin structure. (A) VCE-003 notably reduces microglial
activation (Iba1+ cells). (B) Quantification of Iba1+ cells are shown as means 6 SEM (***p,0.001 vs Intact; #p = 0.021 vs EAE + VEH). Thoracic spinal
cord sections from symptomatic animals show a clear disruption of myelin, whereas exposure to VCE-003 contributes to maintain the myelin
structure (C, RIP immunofluorescence staining; D, LFB staining).
doi:10.1371/journal.pone.0094733.g005
Cannabigerol Quinone and EAE Pathogenesis
PLOS ONE | www.plosone.org 9 April 2014 | Volume 9 | Issue 4 | e94733
Figure 6. VCE-003 reduces axon damage. Representative images of axon morphology changes: (A) transversal thoracic spinal cord sections,
neurofilament staining in red; (B) longitudinal thoracic spinal cord sections, neurofilament staining in green (please note axon swelling, arrows). (C)
VCE-003 treatment helps to preserve the axon structure as showed in longitudinal thoracic spinal cord sections by SMI32 staining.
doi:10.1371/journal.pone.0094733.g006
Figure 7. VCE-003 reduces the expression of inflammatory marker mRNAs in the spinal cord and of iNOS protein in BV2 cells. VCE-
003 decreased the mRNA expression of TNFa, IFNc, IL-1b and IL-17 (A), and the adhesion molecule ICAM-1 and iNOS (B). (C) Immunoblotting of iNOS.
Proteins in lysates (30 mg) from BV2 cells stimulated with LPS (50 ng/ml) and IFNc (100 u/ml), and pre-treated with VCE-003 (1 mM). Both CB2 and
PPARc antagonists (AM630 1 mM and GW9662 0.1 mM, respectively) were administered 10 min before than VCE-003 treatment. The results are
presented as the relative ratio of proteins, where the iNOS signal obtained by densitometric analysis was normalized to the tubulin signal. VCE-003
treatment significantly reverses the LPS-IFNc-induced effects to the control situation, and both CB2 and PPARc antagonists blocked this effect of VCE-
003. The results in (A, B) are shown as the means 6 SEM: *p = 0,011 vs Intact (TNFa); *p = 0,003 vs Intact (ICAM-1); **p,0.01 vs Intact; #p = 0.05 vs EAE
+ VEH (ICAM-1); ##p,0.01 vs EAE + VEH; ###p,0.001 vs EAE + VEH). The results in (C) are shown as the means 6 SEM from three independent
experiments performed in triplicate: ***p,0.001 vs CTL; ##p,0.01 vs CTL + LPS- IFNc; +p = 0.034 vs VCE-003 1 mM + LPS- IFNc; ++p = 0.002 vs VCE-
003 1 mM + LPS- IFNc.
doi:10.1371/journal.pone.0094733.g007
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the progression of MS and EAE [5,25]. When microglia/
macrophages are activated they release some cytotoxic mediators
that may provoke tissue injury, including pro-inflammatory
cytokines like IL-1b, IFNc, IL-6, TNFa, nitric oxide (NO) and
ROS, [26,27]. However, most importantly, several cytokines can
reactivate microglia, which leads to feed-forward regulation of
inflammation. The decrease in Iba-1 immunoreactivity following
VCE-003 treatment reflected the reduced microglial activation in
EAE mice. This observation suggests that VCE-003 might
ameliorate EAE symptoms by dampening microglial activation
in the spinal cord, thereby impairing important inflammatory steps
that lead to the damage of myelin and axons. In support of this
hypothesis, we found a decrease in the expression of mRNA
transcripts encoding the cytokines TNFa, IFNc and IL-1b in the
spinal cord of VCE-003 EAE-treated mice, together with a
marked reduction in the mRNA transcripts encoding the adhesion
molecule ICAM-1 and iNOS. In addition, direct evidence that
microglial cells are targets for VCE-003 [20] was confirmed when
it was shown to reverse the increase in iNOS protein in activated
murine BV2 microglial cells through a mechanism that involves
PPARc and CB2 receptors, supporting our findings on disease
severity scores.
Myelin-specific CD4+ Th1 and Th17 cells [21] with the
contribution of CD8+ T cells [28,29], is one of the major driving
forces in the pathological process of EAE. Here, we show that
there were fewer CD4+ T cells in the spinal cord of EAE mice after
VCE-003 administration and thus, the improvement in spinal cord
damage may be associated with decreased CD4+ T cell infiltration
from peripheral tissues. In this sense, we have shown that VCE-
003 inhibits peripheral primary T cell activation and proliferation,
as well as the release of Th1 and Th17 cytokines or chemokines.
Although the lipophilic nature of VCE-003, like other pCBs,
predicts it will penetrate into the CNS, it is possible that VCE-003
may also exert its effects at the level of the peripheral immune
response. Accordingly, it is noteworthy that VCE-003 inhibits IL-
17-mediated production of pro-inflammatory cytokines in macro-
phages and perhaps, the migration of pro-inflammatory macro-
phages to the CNS.
Preclinical and clinical data have shown that Th17 cells are
associated with several autoimmune diseases, such as MS [11],
arthritis, psoriasis and lupus. In the present study, IL-17 mRNA
expression was reduced in the spinal cord of EAE mice
administered VCE-003. In vitro approaches indicated that VCE-
003 was capable of reducing the transcription of IL-17, and it was
more effective in inhibiting TNFa release than TNFa-gene
promoter activity. On this basis, VCE-003 possibly inhibits
cytokine release at both the transcriptional and post-transcription-
al level. Since we found that VCE-003 inhibited IL-17 signaling in
macrophages we cannot rule out the possibility that a similar
situation may also occur also in primary T cells. If this were the
case, IL-17 released in CD3/CD28-stimulated T cells could act in
an autocrine manner, increasing the stability of other CD3/CD28-
induced cytokine mRNAs, an activity that could also be inhibited
by VCE-003 [30,31]. Although PPARc and CB2 are the more
relevant targets for VCE-003 we cannot discard that other
mechanism(s) of action are also involved in the immunosuppressive
activity of VCE-003. In this sense it is also possible that the effect
of VCE-003 on cytokine expression is reflecting inhibition of T cell
proliferation mediated by targeting downstream signal pathways
other than PPARc and CB2, which prevent proliferation and
subsequently cytokine production. We are currently performing
experiments to identify the exact mechanism of action of VCE-003
in TCR-induced and IL-17R-induced signaling pathways.
The CNS has several protective antioxidant mechanisms that
are regulated through the nuclear factor–E2-related factor
transcription factor (Nrf2) and the antioxidant response element
(ARE). In MS, Nrf2/ARE expression is enhanced and this is
indicative of a response to oxidative stress. Moreover, disruption of
Nrf2 gene expression in mice exacerbates the clinical and
pathological symptoms of EAE [32]. Here, we found that VCE-
003 activates the Nrf2 pathway in several neuronal cell lines
(Figure S2 in File S1). Nrf2 is a major influence in the upregulation
of multiple antioxidant defense systems in response to oxidative
stress [33]. Uncontrolled or excessive oxidative stress may increase
the expression of Nrf2 mRNA, as observed in EAE mice, probably
as a primary mechanism to suppress aberrant oxidative stress
responses and to promote protection from inflammatory disease.
However, it should be noted that VCE-003-treated EAE mice
showed reduced Nrf2 transcripts and no changes in Nrf2-
dependent gene expression Hmox-1 (Figure S3 in File S1). The
discrepancies between the in vitro and in vivo results may be due to
the fact that Nrf2 expression was assessed at the end of treatment,
when the clinical scores of the mice that received VCE-003 were
less than 1 and therefore, these EAE mice showed a clear clinical
improvement.
BBB integrity is critical to regulate the infiltration of migrating
cells into the CNS. ICAM-1 was expressed strongly in acute MS
lesions and comparable levels were also detected in chronic-active
MS lesions, whereas the expression of VCAM-1 was greatly
increased in chronic-active MS lesions compared to in acute MS
[34,35]. In the EAE model, many studies have demonstrated
changes in adhesion molecules that reflect alterations to the BBB
[36]. We have recently shown that VCAM-1 is reduced in the
spinal cord of TMEV-infected mice that were administered VCE-
003 [20]. In keeping with the fact that VCAM-1 expression is
critical to allow lymphocyte trafficking from the periphery to the
CNS, we showed a decrease in spinal cord infiltrates and
specifically, decreased CD4+ T cells. Collectively these data may
explain why immunized mice that receive VCE-003 display a
notable alteration in disease onset and severity, in terms of reduced
symptomatology and inflammation. Remarkably, VCE-003 treat-
ed mice develop significantly less paralysis and histological signs of
EAE, and concordantly, they display weaker expression of the
canonical Th1 cytokine IFNc and the Th17 cytokine, IL-17A. As
VCE-003 acts as an agonist of both CB2 and PPARc receptors,
and the activation of these receptors has been linked with anti-
inflammatory effects in EAE [37,38], we showed that the blockade
of these receptors significantly attenuated the anti-inflammatory
effects of VCE-003 in microglia. Although more work is needed to
determine the cellular and molecular targets of VCE-003, and to
clearly establish the signaling pathways involved in its actions, the
unique capacity of VCE-003 to simultaneously repress IL-17
expression, microglial activity and CNS infiltrates suggests that it
may be useful to manage MS. This CBG derivative appears to be
a novel compound for inflammatory diseases.
Conclusions
The primary findings of this study show that VCE-003 is an
immunosuppressive compound targeting PPARc and CB2 recep-
tors. VCE-003 inhibits Th1 and Th17 responses and IL-17-
induced polarization of M1 macrophages. Treatment with VCE-
003 attenuated EAE in mice and we observed a reduction of CD4+
cells infiltrates in the spinal cord accompanied by decreased
microglial activation, myelin sheets structure preservation and
reduced axonal damage. At the concentration tested VCE-003
does not show cytotoxicity in primary T cells and represents a
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potential therapeutic agent for the treatment of human diseases
with both inflammatory and autoimmune components.
Supporting Information
File S1 Figures S1–S3. Figure S1. Effects of VCE-003 on
cytokines and chemokines in T cells. Human peripheral T cells
were stimulated for 72 h with the OKT3 (1 mg/ml) and anti-
CD28 (0.5 mg/ml) mAbs in the presence or absence of increasing
concentrations of VCE-003, and the culture supernatants were
collected and assayed for cytokines and chemokines. Original X-
ray films from the detection of cytokines and chemokines using the
semiquantitative Human Cytokine Array Kit, Panel A (R&D
System; Minneapolis, MN, USA). Figure S2. VCE-003 effects in
Nrf2 transcription in different cell lines. The cells were transfected
with the ARE-Luc plasmid and then stimulated with either CBG
or VCE-003 for 6 h. The luciferase activity was measured and
results are presented as the fold induction over untreated cells. The
results are expressed as the means 6 SEM of three determinations
in triplicate. Statistical analysis: *p,0.05; **p,0.01; ***p,0.001
vs controls. Figure S3. VCE-003 effects in Nrf2 and Hmox-1
mRNA expression in spinal cord of EAE mice. Levels of mRNA
expression for Nrf2 and Hmox-1 in EAE mice that received
vehicle and EAE mice treated with VCE-003. *p,0.05 vs Intact;
#p,0.05 vs EAE + vehicle.
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